SAN DIEGO—Data from the TENERE study show that teriflunomide and interferon beta-1a have similar risk of failure in treating patients with relapsing forms of multiple sclerosis (MS). These data also indicate that once-daily teriflunomide is well tolerated at both the 7-mg and 14-mg doses and that the rate of permanent discontinuation is lower in patients receiving teriflunomide than in patients receiving interferon beta-1a, researchers reported at the Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in MS.
TENERE is a randomized, multicenter, parallel-group, rater-blinded study of 324 patients with relapsing MS. Patrick Vermersch, MD, of the University of Lille Nord de France, and colleagues, compared the effectiveness and safety of teriflunomide, an oral disease-modifying therapy in development for treatment of relapsing MS, with that of subcutaneous interferon beta-1a.
Patients randomized to teriflunomide received either a 7-mg or 14-mg dose once daily, while those randomized to interferon beta-1a (albumin-free formula) received therapy three times weekly. “Approximate range of treatment duration for completers was 48 to 114 weeks,” the investigators stated.